Coenzyme A and Visceral Fat: What the Evidence Shows

Coenzyme A and visceral fat are linked through fundamental metabolic pathways that govern how the body stores and burns fat. Coenzyme A (CoA) sits at the centre of fatty acid oxidation and energy production, making it a molecule of genuine scientific interest in the context of metabolic health. Visceral fat, which accumulates around internal organs, carries significant cardiometabolic risk and is influenced by the same pathways in which CoA plays a key role. This article explores what the current evidence says about CoA, its precursors, and whether targeting these pathways can meaningfully reduce visceral fat.

What is Coenzyme A and how does it affect body fat?

Coenzyme A is a carrier molecule derived from pantothenic acid that directs acetyl groups into energy production or, when energy is surplus, towards fatty acid and cholesterol synthesis, influencing fat accumulation.

Coenzyme A (CoA) is a molecule found in every cell of the body that plays a central role in fat metabolism, energy production and the synthesis of fatty acids. It is derived from pantothenic acid (vitamin B5) and acts as a carrier molecule, shuttling acetyl groups into the citric acid cycle to generate energy.^[1][2] Clinically significant pantothenic acid deficiency is rare in the UK, and CoA is not usually rate-limiting under normal physiology in people eating a varied diet. The relevance of CoA to fat metabolism is therefore most apparent in the context of broader metabolic regulation rather than everyday deficiency.

In practical terms, CoA sits at a metabolic crossroads. When energy intake exceeds expenditure, excess acetyl-CoA is redirected away from energy production and towards the synthesis of new fatty acids and cholesterol, contributing to fat accumulation. Conversely, during periods of caloric restriction or increased physical activity, CoA facilitates the mobilisation and oxidation of stored fat, including adipose tissue around the organs.

CoA is also involved in the regulation of gene expression related to lipid metabolism through its role in protein and histone acetylation, a mechanism described in biochemistry literature on epigenetic regulation. Some research has suggested that declining CoA availability with ageing may impair the body's capacity to clear dysfunctional cellular components through a process called autophagy, potentially contributing to fat accumulation over time. However, this evidence comes largely from animal and in vitro studies; robust human evidence linking age-related CoA changes to autophagy impairment and adiposity is limited, and these claims should be regarded as preliminary.

It is important to note that CoA itself is not a supplement that can be taken directly in a meaningful way, as it does not cross cell membranes efficiently. Interest has therefore focused on its precursors, particularly pantothenic acid and pantethine, as potential ways to support CoA-dependent metabolic pathways.

Why is visceral fat more harmful than fat under the skin?

Visceral fat releases free fatty acids and pro-inflammatory cytokines directly into the portal circulation, promoting insulin resistance, liver disease and systemic inflammation, making it more harmful than subcutaneous fat.

Visceral fat, which accumulates around internal organs such as the liver, pancreas and intestines, is metabolically more active and more harmful to health than subcutaneous fat, which sits beneath the skin. Unlike subcutaneous fat, visceral fat releases fatty acids and inflammatory signalling molecules directly into the portal circulation, meaning they reach the liver before being diluted in the general bloodstream.^[22][23]

This proximity to the liver has significant consequences. Elevated free fatty acid delivery to the liver promotes insulin resistance, increases triglyceride synthesis and contributes to metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as non-alcoholic fatty liver disease or NAFLD). Visceral fat also secretes pro-inflammatory cytokines, including interleukin-6 and tumour necrosis factor-alpha, which drive low-grade systemic inflammation. This inflammatory state is associated with an increased risk of type 2 diabetes, cardiovascular disease and certain cancers.

NICE guidance on obesity and cardiovascular risk recognises waist circumference as a clinically relevant measure alongside body mass index (BMI). UK guidance uses two risk bands for waist circumference. For white European adults, a waist circumference above 94 cm in men or above 80 cm in women indicates increased cardiometabolic risk, and above 102 cm in men or above 88 cm in women indicates high risk. Lower thresholds apply for some ethnic groups, including South Asian, Chinese and Japanese adults, reflecting greater cardiometabolic risk at smaller waist sizes.^[19][24] Patients should discuss which thresholds apply to them with their GP or practice nurse.

NICE also recommends considering waist-to-height ratio as a complementary measure: a ratio of 0.5 or above indicates increased health risk in most adults. The NHS provides guidance on how to measure waist correctly, and the NHS Eatwell Guide supports broader healthy weight messaging.

Subcutaneous fat, while not entirely benign in large quantities, behaves differently. It acts partly as a metabolic buffer, storing excess energy in a relatively inert form. The distinction matters clinically because two individuals with the same BMI can have very different visceral fat burdens and therefore very different levels of metabolic risk.

Can boosting Coenzyme A levels help reduce visceral fat?

No supplement targeting CoA or its precursors is currently recommended by NICE, the NHS or the MHRA for visceral fat reduction, as robust human clinical evidence is lacking.

There is currently no robust clinical evidence that directly boosting CoA levels in humans leads to a measurable reduction in visceral fat. The hypothesis is scientifically plausible, given CoA's central role in fatty acid oxidation and autophagy, but translating this into a practical intervention remains challenging. Most of the relevant research has been conducted in animal models or in vitro, and findings do not always translate reliably to human physiology.

Pantethine, a stable derivative of pantothenic acid and a direct precursor to CoA, has been studied in small human trials for its effects on lipid profiles. Some studies have reported modest reductions in total cholesterol and triglycerides, which are markers associated with visceral fat accumulation. However, these trials have generally been small, short in duration and not specifically designed to measure visceral fat by imaging techniques such as MRI or CT scanning. The evidence base is therefore insufficient to draw firm conclusions about any effect on visceral fat specifically.

Research into NAD+ precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) has attracted attention partly because NAD+ and CoA share overlapping roles in mitochondrial energy metabolism. Some animal studies have shown reductions in visceral fat with NAD+ supplementation, but human evidence from randomised controlled trials remains limited and inconclusive. NR and NMN should not be assumed to act equivalently to CoA precursors, as their metabolic pathways differ. Some NMN and NR products may also be subject to novel food regulations in the UK; the Food Standards Agency (FSA) provides guidance on the legal status of food supplements and novel foods.

No supplement targeting CoA or its precursors is currently recommended by NICE, the NHS or the MHRA as a treatment for visceral fat or obesity. Anyone concerned about visceral fat accumulation should discuss evidence-based options with their GP, which may include lifestyle interventions or, where clinically appropriate, pharmacological treatment. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where clinically appropriate options can be explored.

What does the current evidence say about safety and side effects?

Pantothenic acid is generally safe at dietary levels, but high-dose CoA precursor supplements lack long-term safety data and are not subject to MHRA pre-market efficacy evaluation.

Pantothenic acid (vitamin B5), the dietary precursor to CoA, is generally considered safe at the levels found in food and in standard multivitamin supplements. The European Food Safety Authority (EFSA) has evaluated pantothenic acid and has not established a tolerable upper intake level, reflecting the absence of reported adverse effects at high dietary intakes. However, this does not mean that high-dose supplementation is without risk, and caution is warranted when taking any nutrient in amounts far exceeding dietary reference values.

Pantethine supplements, which are more directly active as CoA precursors, have been used in clinical studies at doses of 600 to 900 mg per day without significant adverse effects being reported in the short term. Mild gastrointestinal symptoms, including nausea and loose stools, have been noted in some participants. Long-term safety data in humans are limited, and no large-scale randomised controlled trials have been conducted to establish a comprehensive safety profile.

People who are pregnant or breastfeeding, children, and individuals with significant comorbidities such as liver or kidney disease should avoid high-dose supplements unless specifically advised by a clinician. Anyone taking prescribed medicines should seek medical advice before starting supplements, as interactions cannot be excluded.

Healthcare professionals and patients should be aware that supplements marketed for fat metabolism or CoA support are not regulated as medicines in the UK. They are classified as food supplements and are not subject to the same pre-market efficacy and safety evaluation required of licensed medicines by the MHRA. This means that quality, purity and dosing consistency can vary between products. The FSA and GOV.UK provide guidance on food supplement regulation in the UK.

Anyone experiencing unexpected symptoms while taking supplements, including gastrointestinal disturbance, skin reactions or fatigue, should stop taking the product and consult their GP. Suspected adverse reactions to any product can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. If symptoms are severe or rapidly worsening, contact NHS 111 for urgent advice.

Lifestyle and dietary approaches to support healthy fat metabolism

Dietary modification, regular aerobic and resistance exercise, and adequate sleep are the most robustly evidenced approaches to reducing visceral fat, supported by NICE and UK Chief Medical Officers' guidelines.

The most robustly evidenced approaches to reducing visceral fat and supporting healthy fat metabolism remain dietary modification, regular physical activity and adequate sleep, all of which influence CoA-dependent metabolic pathways indirectly. NICE guidance on weight management recommends a sustained caloric deficit achieved through a balanced diet, combined with increased physical activity, as the foundation of any weight management strategy. Patients should confirm the most current NICE guideline reference with their clinician, as guidance is periodically updated.

Dietary sources of pantothenic acid, which supports CoA synthesis, include:

• Wholegrains such as oats and brown rice

• Legumes including lentils and chickpeas

• Eggs, poultry and lean meat

• Avocado and mushrooms

• Fortified breakfast cereals

A varied, balanced diet in line with NHS Eatwell Guide principles is likely to provide sufficient pantothenic acid for normal CoA function without the need for supplementation in most healthy adults.

Aerobic exercise, particularly moderate-intensity continuous training and high-intensity interval training (HIIT), has been shown in multiple systematic reviews and meta-analyses to reduce visceral fat independently of changes in total body weight. Resistance training also contributes by increasing lean muscle mass, which raises basal metabolic rate and improves insulin sensitivity, both of which support fat oxidation. The UK Chief Medical Officers' Physical Activity Guidelines recommend at least 150 minutes of moderate-intensity activity per week for adults, alongside muscle-strengthening activities on two or more days per week.^[13][14]

Sleep quality and duration are increasingly recognised as important regulators of fat metabolism. Chronic sleep deprivation is associated with elevated cortisol, increased appetite and preferential accumulation of visceral fat. NHS guidance recommends seven to nine hours of sleep per night for most adults.^[16][17]

For individuals who have not achieved meaningful reductions in visceral fat through lifestyle measures alone, a GP assessment is the appropriate next step. This may include evaluation for underlying metabolic conditions and discussion of evidence-based pharmacological or surgical options where clinically indicated.

Scientific References

1. Biosynthesis of Pantothenic Acid and Coenzyme A.
2. Brain CoA and Acetyl CoA Metabolism in Mechanisms of Neurodegeneration.
3. Coenzyme A biosynthetic machinery in mammalian cells.
4. Signalling functions of coenzyme A and its derivatives in mammalian cells.
5. Coenzyme A: to make it or uptake it?.
6. Novel formulations of supplement compounds designed to increase oral bioavailability.
7. Importing food supplements and health foods.
8. Aerobic Exercise and Weight Loss in Adults: A Systematic Review and Dose-Response Meta-Analysis.
9. A dose-response relation between aerobic exercise and visceral fat reduction.
10. Comparative Efficacy of Exercise Type on Visceral Adipose Tissue in Patients With Prediabetes and Type 2 Diabetes Mellitus: A Systematic Review With Pairwise and Network Meta-Analyses.
11. Effect of low-volume interval training on whole-body, abdominal and visceral fat in adults living with overweight and obesity: A systematic review and meta-analysis.
12. Efficacy of Interval Training in Improving Body Composition and Adiposity in Apparently Healthy Adults: An Umbrella Review with Meta-Analysis.
13. Physical activity guidelines: UK Chief Medical Officers' report.
14. UK Chief Medical Officers' physical activity guidelines (full guidance text).
15. Physical activity guidelines for adults aged 19 to 64.
16. Sleep problems – Every Mind Matters.
17. Insomnia.
18. Overweight and obesity management (NG246): Identifying and assessing overweight, obesity and central adiposity.
19. NG246 Appendix A1: Summary of evidence from surveillance (waist circumference thresholds for ethnic groups).
20. Calculate your waist to height ratio.
21. NICE waist-to-height ratio guidelines 'to have a waist <0.5'.
22. Male Obesity and Cardiometabolic Risk: Inflammatory Mechanisms and Clinical Implications.
23. Metabolic Dysfunction-Associated Steatotic Liver Disease and Respiratory Disorders: A Systematic Review of Clinical and Pathophysiological Associations.
24. Obesity, abdominal obesity, and adipose tissue depots in South Asians with specific reference to Asian Indians: Implications of New Obesity Guidelines.
25. Proposing new body mass index and waist circumference cut-offs based on cardiometabolic risks for a Central Asia population: A feasibility study.

Frequently Asked Questions